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It has been suggested that multiple myeloma (MM), a clonal 
B-cell malignancy involving plasma cells, arises from a typical
stepwise neoplastic transformation (Hallek et al, 1998). With 
the accumulation of progressive genetic events that favour 
proliferative advantages and the expansion of the mutant cell 
clone, MM proceeds from non-proliferating normal plasma 
cells to those with extended lifespan, then with potential of
immortal growth, and finally with a neoplastic phenotype. In rela-
tion to clinical progression, immortalization and transformation 
steps generally correspond to monoclonal gammopathy of un-
determined significance (MGUS) and MM, respectively (Hallek 
et al, 1998). 
The process of MM pathogenesis as indicated above is appar-
ently similar to the in vitro immortalization and transformation
model represented by viral and cellular oncogene-transformed
somatic cells. It has been proposed that activation of telomerase
and subsequent stabilization of telomere length is a critical step for
in vitro cellular immortalization (Harley et al, 1994). Telomerase,
an RNA-dependent polymerase, synthesizes telomere TTAGGG
repeat sequences at the ends of chromosomes required for the
integrity and stability of linear chromosomes (Harley et al, 1994).
Normal somatic cells, generally lacking telomerase activity,
display progressive attrition of telomeric DNA with each round of
cell division since conventional DNA polymerase is unable to
fully replicate linear DNA molecules and the cells eventually
undergo senescence when a threshold telomere length is reached
(Harley et al, 1994). Telomere shortening is thus suggested to act
as a mitotic clock which records cellular replicative history and
limits cellular proliferative lifespan. Accumulated evidence has
demonstrated that most human tumour cells override the mitotic
clock barrier and stabilize their telomere length via activating
telomerase (Harley et al, 1994). The prevalence of telomerase ac-
tivation has been observed not only in cultured immortal cell lines
but also in the vast majority of human primary malignancies. The
specific link of telomerase activation with cell immortalization
and human cancers makes it a useful diagnostic marker and an
attractive target for cancer therapy. 
Besides telomerase, telomere length is apparently regulated
by some other factors. A novel poly (ADP-ribose) polymerase
named tankyrase has recently been identified and it may allow
telomerase to approach the chromosome ends and to elongate
telomeres (Smith et al, 1998). Although tankyrase is widely
expressed in human normal tissues/cells, the highest level of
tankyrase mRNA was detected in testis that also exhibits strong
telomerase activity. It is currently unclear how tankyrase is 
regulated and whether it plays a role in human primary 
malignancies. 
The spectrum MGUS-MM-PCL provides an example to analyse
telomerase activation during in vivo tumorigenesis. Given that
activation of telomerase is a prerequisite for cellular immortaliza-
tion, it would be expected that both MGUS and MM exhibit 
telomerase activity based on the pathogenesis model of MM
suggested by Hallek and co-workers (1998). To test this hypoth-
esis, we examined telomerase activity and its implications in
plasma cells from patients with MGUS, MM and PCL. In addition, 
the expression of the telomerase components telomerase reverse
transcriptase (hTERT), telomerase RNA template (hTER) and
tankyrase was assessed in the samples in order to elucidate 
their role in telomerase activation or regulation in plasma cell
dyscrasias. 
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Summary Activation of telomerase is essential for in vitro cellular immortalization and tumorigenesis. In the present study, we investig-
ated telomerase activation and its implications in plasma cell dyscrasias including monoclonal gammopathy of undetermined significance
(MGUS), multiple myeloma (MM) and plasma cell leukaemia (PCL). All 5 patients with MGUS exhibited normal levels of telomerase activity in
their plasma cells. Elevated telomerase activity was found in the samples from 21/27 patients with MM and 4/4 with PCL. In addition, 4
myeloma cell lines all expressed high levels of telomerase activity. The expression of telomerase reverse transcriptase (hTERT) and
telomerase RNA template (hTER) was positively associated with the levels of telomerase activity in MM/PCL. Tankyrase expression was
upregulated, concomitant with the induction of hTERT and activation of telomerase in MM/PCL. The present findings indicate that MGUS cells
may not be immortalized and that activation of telomerase plays a role in the malignant transformation from MGUS to MM. © 2001 Cancer
Research Campaign http://www.bjcancer.com
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Patients 
The study was performed on bone marrow (BM) plasma cells from
5 patients with MGUS, 27 with MM (4, 8, and 15 with stages I, II
and III, respectively) and on peripheral blood plasma cells from 4
patients with PCL. The median age of the patients was 67 years
(range 40–80). In addition, BM aspirates of 5 adult patients with
non-malignant disorders were included as controls. The clinical
staging of MM was defined according to the criteria proposed by
Salmon and Durie (Durie and Salmon, 1975). Two patients had a
Bence Jones, and one a non-secretory MM. 13 MM, and one PCL
patient had received chemotherapy before sampling. 
Bone marrow samples 
BM was drawn into heparinized glass tubes, and mononuclear
cells were isolated with Ficoll-Paque (Pharmacia, Uppsala,
Sweden) gradient centrifugation and washed in phosphate
buffered saline (PBS). The cells were either subjected to CD38bright
subpopulation separation or frozen to –160˚C in a programmed
freezer in 90% human AB serum and 10% dimethylsulphoxide
(DMSO) and thereafter stored in liquid nitrogen. Prior to analysis,
the frozen cells were rapidly thawn at 37˚C, resuspended in 100%
FCS, centrifuged to remove DMSO and dead cells, and finally
washed twice with ice-cold PBS. The viability of cells was above
90% as determined by trypan blue exclusion. 
CD38bright plasma cell isolation 
CD38 was chosen as a marker for plasma or MM cells (Yi et al,
1997). 2–5 ´ 107 BM mononuclear cells, fresh or newly thawn,
were incubated with CD38 monoclonal antibody conjugated with
R-phycoerythrin (R-PE) and then sorted by Mini-Magnetic Cell
Sorting kit (Miltenyi Biotec, Sunnyale, CA, USA) according to the
manufacturer’s recommendations. Earlier results showed that the
purity of CD38bright cells was around 70% for samples with less
than 15% plasma cells in BM and 80% or more for samples with
³15% of plasma cells as determined by flow cytometry (Yi et al,
1997). In the present study, the purity of the sorted cells were
examined in samples from 3 patients (2 MGUS and 1 MM) with
3.3%, 5% and 9% plasma cells in their BM, respectively. The
CD38bright cell purity after sorting was 71%, 73% and 91%, respec-
tively. The purified CD38bright and CD38 negative cells were stored
at –80˚C until use. 
Cell lines and cell culture 
The REH cell line, derived from a human pre-B lymphocytic
leukaemia, and 4 myeloma cell lines Karpas-707, HL-4076, U266
and LP-1 (kindly provided by Professor K Nilsson, Uppsala
University, Sweden) were grown in RPMI 1640 medium (Gibco,
Glasgow, UK) supplemented with 10% fetal calf serum, 2 mM L-
glutamine and 100 U ml–1 penicillin at 37˚C in humidified 5%
CO2/95% air atmosphere. 
Telomerase activity assay 
Cells (2 ´ 105–2 ´ 106) were suspended in ice-cold standard lysis
buffer (Kim et al, 1994). Protein extraction and measurement was
performed as described (Xu et al, 1996, 1998). A commercial
telomerase PCR ELISA kit (Roche Diagnostics Scandinavia AB,
Stockholm, Sweden), based on Telomeric Repeats Amplification
Protocol (TRAP) introduced by Kim et al (1994), was used to
determine telomerase activity in all samples in duplicate according
to the manufacturer’s protocol. In a prior study we demonstrated
that input of 0.5 mg of protein with 28 cycle PCR amplification
and 3 ml of the PCR products for ELISA detection gave optimal
and reproducible signals within exponential phase for telomerase
activity detection (Xu et al, 1998). The level of telomerase activity
in samples or cell lines was expressed as the percentage of that in
the same amount of protein derived from REH cells. 
RNA extraction, reverse transcription and RT-PCR 
Total cellular RNA from isolated plasma cells was extracted using
the Ultraspec™-II RNA kit (Biotecx Lab., Houston, TX, USA).
RNA yield and purity were determined spectrophotometrically at
260/280 nm. cDNA was synthesized using random primers (N6)
(Pharmacia, Uppsala, Sweden) and MMLV reverse transcriptase
as described (Xu et al, 1998). PCR primers for tankyrase were:
(Forward) 5¢CCCGACTTCTTCCTCATCTTC3¢ and (Reverse)
5¢GCGTCCACCAGCCTCTTTA3¢. The resulting PCR product
was 210 bp fragments. cDNA derived from 50 ng RNA in total
25 ml reaction mixture (1 ´ PCR buffer, 0.25 mM MgCl2, 0.25 mM
each dNTP, 0.625 U Taq polymerase and 0.06 mM each primer)
was amplified in DNA thermal cycler 9600 (Perkin Elmer) using
29 cycles (94˚C 30², 60˚C 30² and 72˚C 45²). PCR conditions and
primers for hTERT and hTER were described elsewhere (Xu et al,
1998), and amplification cycles were 34 and 30 for hTERT and
hTER, respectively. In addition, b2-microglobulin (b2-M) expres-
sion was used as a control for RNA loading and RT efficiency and
amplified during 25 PCR cycles (94˚C for 30², 60˚C for 30² and
72˚C for 60²) (Xu et al, 1998). In each PCR, cDNA from REH
cells and H2O were included as positive and negative controls,
respectively. PCR products were resolved in 2% agarose gels
stained with ethidium bromide, visualized in UV light and
photographed. Volumetric integration of signal intensities was
performed by using the NIH Image software (Version 1.61). The
relative levels of each gene expression were arbitrary values calcu-
lated from the ratio of the target to b2-M. 
Statistical analyses 
Unpaired Student t-test was used to compare differences of telom-
erase activity between two groups. A correlation of telomerase
activity with the percentage of plasma cells in BM or with hTERT,
hTER and Tankyrase expression was tested with a simple regres-
sion analysis. All statistical analyses were performed using
StatView 4.5 software produced by Abacus Concepts Inc.
(Berkeley, CA, USA). The level of significance was set to a P
value < 0.05. 
RESULTS 
Telomerase activity in BM mononuclear cells from
control BM samples 
Normal human peripheral blood mononuclear cells and BM
mononuclear cells exhibit weakly detectable telomerase activity
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We have previously shown that telomerase activity in normal
PBMCs ranged from 3–8% of that in REH cells, as determined
using Telomerase PCR ELISA kit (Xu et al, 1998). Similar base-
line levels of telomerase activity (0–9%) were found in BM
mononuclear cells from 5 adult patients with non-malignant dis-
orders (Figure 1). Accordingly, a telomerase activity value beyond
10% was defined as higher than normal. 
Telomerase activity in MM cell lines and in plasma cells
from patients with MGUS, MM and PCL 
All 4 MM cell lines Karpas-707, HL-4076, U266 and LP-1 cells
expressed strong telomerase activity ranging 71–117% of that in
REH cells. Telomerase activity was within normal levels in plasma
cells from all 5 patients with MGUS. The 4 samples from patients
with PCL varied between 54 and 78%. Telomerase activity varied
considerably in the samples from patients with MM, 1–101%. 21
of the 27 samples from patients with MM had elevated telomerase
activity (2/4, 5/8, and 14/15 of the samples from patients with
stages I, II and III disease, respectively). It seemed that the patients
with the advanced disease were more likely to have increased
telomerase activity in their plasma cells (Stage III vs I and II, 
P = 0.06, Fisher’s exact test). However, there was no difference 
in mean telomerase activity in stages I, II and III (35.8 ± 38.7, 
23.8 ± 15.8 and 48.4 ± 32.5, respectively, mean ± SD). As seen in
Figure 1, telomerase activity exhibited a pattern as following: 
PCL > MM > MGUS. 
The mean percentage of plasma cells in BM of patients with
MM was 45.3 ± 30.9. There was no correlation between the
percentage of plasma cells in bone marrow and telomerase activity
(r2 = 0.039, P = 0.32). In addition, no relationship was found
between the size in the M-component and the levels of telomerase
activity. Mean telomerase activity did not differ between samples
from patients with MM/PCL, who received prior cytostatic treat-
ment (n = 14) and those who did not (n = 17). 17 patients (4 stage
II, 12 stage III and 1 PCL) received cytostatic treatment after
sampling. Of 14 evaluable patients, 7 responded to chemotherapy
with at least 25% reduction of the M-component. There was no
significant difference in telomerase activity in plasma cells
between patients with responding and unresponsive disease
(32.6 ± 22.8 vs 53.7 ± 36.5, P = 0.22). 
Correlation of hTERT, hTER and tankyrase expression
with telomerase activity in MM/PCL 
To explore possible pathways that affect telomerase activity in
plasma cells from patients with MM, the expression of telomerase
components hTERT, hTER and newly identified tankyrase, implic-
ated in telomerase function regulation, was determined in 10
samples from MM/PCL patients. The expression of hTERT
mRNA was positively correlated with the levels of telomerase
activity (r2 = 0.67, P = 0.004, Figure 2A). There was also a signi-
ficant positive association between hTER expression and telom-
erase activity (r2 = 0.45, P = 0.04, Figure 2B). Interestingly, the
expression of tankyrase appeared to have a weak correlation 
with telomerase activity (r2 = 0.29, P = 0.1, Figure 2C), but was
significantly related to the hTERT mRNA expression (r2 = 0.62, 
P = 0.007). 
DISCUSSION 
In the present study, we found elevated telomerase activity in 78%
of MM, all of 4 PCLs and 4 MM cell lines. By contrast, telomerase
activity was at normal levels in 5 MGUS samples. In a recent study
of 31 patients with MM, telomerase activity was found to be
considerably variable. High levels correlated to the presence of
chromosomal changes (Orme et al, 1999). Cheryk et al (1999)
showed that telomerase activity was present in plasma cells from
12 of 15 MM patients but absent in all 5 patients with MGUS.
Taken together, the data suggest that the activation of telomerase
may play a role in the malignant transformation from MGUS to
MM. 
The finding that telomerase activity was not increased in MGUS
cells indicates that those cells are not immortal, which is appar-
ently incompatible with the concept that MGUS cells are immortal
as recently suggested by Hallek et al (1998) based on the genetic
analysis data. Earlier studies indeed revealed that MGUS cells had
already acquired several genetic aberrations (Hallek et al, 1998).
These genetic events may affect the regulatory pathways that
directly control cell birth/death, and consequently lead to exten-
sion of the lifespan of MGUS cells. However, the genetic muta-
tions alone in MGUS are not indicators for acquisition of
immortality, since no mutational events in genes responsible for
cell growth control have, to date, been found to be capable of
directly immortalizing normal human cells and immortalization
may occur independently or require multiple genetic alterations
(Harley et al, 1994). Characteristically, those early genetic events
drive the cells to divide far beyond their normal replicative potential,
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Figure 1 Telomerase activity in normal bone marrow cells, monoclonal
gammopathy of undetermined significance (MGUS), multiple myeloma (MM)
and plasma cell leukaemia (PCL) and MM cell lines thus exhaust their telomeric DNA sequences, and eventually
trigger further genetic instability and cellular crisis. During this
process, those cells whose telomerase is activated acquire
immortal phenotype (Harley et al, 1994). MGUS cells have not
extensively expanded yet, there is, thus, no selective advantages
for them to mutate to the immortal phenotype at a pre-neoplastic
stage. In addition, the clinical observation that only a small part of
MGUS eventually progress into MM indicates that in most MGUS
patients the mutant plasma cell clones are unable to circumvent the
limitation imposed by telomere attrition on their replicative
lifespan. 
One may argue that as telomerase activation is not the only
mechanism for maintenance of telomere length, it can not be ruled
out that MGUS cells use alternative pathways (alternative lengthen-
ing of telomeres, ALT) to compensate for the shrinking of telo-
meric DNA sequences caused by cell replication (Bryan et al,
1997). ALT indeed operates in a small subset of tumour cell lines
and in primary malignancies with non-epithelial in origin but is
rare in haematological malignancies (Bryan et al, 1997). This
hypothesis is apparently incompatible with the wide activation of
telomerase observed in MM and PCL. 
It is well documented that extremely short telomeres trigger cell
crisis and subsequent activation of telomerase in in vitro immortal-
ization and transformation model (Harley et al, 1994), however,
defining the exact activation mechanism(s) remains a challenge.
Numerous studies have indicated that telomerase activity is likely
subject to multiple levels of control and regulation by different
factors in different cellular contexts and circumstances. The core
enzyme complex of telomerase consists of hTER and hTERT
(Beattie et al, 1998), so the changes in hTER and hTERT expres-
sion will certainly lead to up- or down-regulation of telomerase
activity. Previous investigations demonstrated that hTER expres-
sion, although readily detected in almost all human tissues/cells
and not always correlated with telomerase activity, was upregul-
ated with tumour progression (Avilion et al, 1996; Sallinen et al,
1997); whereas hTERT, the key component of telomerase, was a
rate-limiting determinant of enzymatic activity in both normal and
neoplastic cells (Meyerson et al, 1997). Consistent with these find-
ings, we found that hTERT and hTER expression positively corre-
lated to the levels of telomerase activity in MM and PCL. It is
poorly understood how hTERT is derepressed during tumorigen-
esis at the moment. A detailed functional analysis on the hTERT
promoter (Cong et al, 1999) will provide new insights into hTERT
regulation and telomerase activation mechanisms in human malig-
nancies including MM. 
In addition, the regulation of telomerase may further operate at a
functional level. Tankyrase allows telomerase to exert its elonga-
tion effect on telomeres. In the present study, tankyrase expression
was found to be positively correlated with hTERT mRNA levels in
MM/PCL cells. Similarly, we found a strong upregulation of
tankyrase expression in activated T cells, concomitant with the
induction of hTERT and telomerase activity (unpublished data).
The data suggest a possible contribution of tankyrase upregulation
in tumour development/progression. 
In summary, we have demonstrated that activation of telomerase
occurs widely in MM and PCL but not in MGUS. The observa-
tions suggest that telomerase activity, although not required for the
pre-neoplastic lesion MGUS, plays a role during stepwise trans-
formation and progression of MM. Upregulation of tankyrase
expression, concomitant with telomerase activation observed in
MM/PCL, may also contribute to tumorigenesis. 
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Figure 2 Correlation of telomerase activity with the expression of
telomerase reverse transcriptase (hTERT) (r2 = 0.67, P = 0.004, (A),
telomerase RNA template (hTER) (r2 = 0.45, P = 0.04, (B), and tankyrase 
(r2 = 0.29, P = 0.1, (C) in multiple myeloma (MM, n = 8) and in plasma cell
leukaemia (PCL, n = 2) ACKNOWLEDGEMENTS 
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